In the rituximab-alone arm of the BEAT-lupus and CALIBRATE trials, serum BAFF levels steadily increased during the trial and were associated with a subsequent rise in serum IgA2 anti-dsDNA antibody levels analyzed using a time-lagged mixed model (Figure 3A). Here, TNFSF13B is linked to systemic lupus erythematosus.